Literature DB >> 31597626

Percutaneous venting gastrostomy/gastrojejunostomy for malignant bowel obstruction: a qualitative study.

Rebecca Singh Curry1, Elizabeth Evans2, Anne-Marie Raftery3, Julia Hiscock4, Marlise Poolman4.   

Abstract

OBJECTIVE: Malignant bowel obstruction (MBO) is a complication of advanced malignancy and is associated with a short prognosis. MBO can infrequently be reversed by surgery or stenting. The focus of treatment is usually symptomatic management, of which percutaneous venting gastrostomy/gastrojejunostomy (PVG) is one consideration. There is little data considering the impact of PVG on quality of life; we therefore aimed to explore this.
METHODS: We identified patients with a PVG inserted for MBO and those who consented to participate were interviewed. The interviews were audio recorded, transcribed and analysed using Framework. Alongside patient interviews, a data collection tool was designed and used to record patient demographics and medical information, enabling us to contextualise individual patients' experiences.
RESULTS: 11 patients were interviewed and 10 patients' data were analysed (1 patient withdrew). No patients regretted having a PVG and many benefitted symptomatically and psychosocially. Challenges encountered included practical issues, pain and PVG tube complications.
CONCLUSIONS: The analysis provided a detailed insight into the impact of PVG insertion and demonstrated that each patient's experience is shaped by a complex interplay of individual factors, thereby highlighting the need to improve referral criteria and individualise patient selection. Other service improvements include enhancing information provision for patients and training for healthcare professionals, thus aiming to mitigate the challenges experienced. Our study is the first in-depth exploration of patients' experiences of PVG at a tertiary cancer centre. Ensuring that the insights from this study are fed back to guide future service provision is critical in enhancing future patient experiences. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  malignant bowel obstruction; patient experience; percutaneous venting gastrostomy; qualitative

Mesh:

Year:  2019        PMID: 31597626     DOI: 10.1136/bmjspcare-2019-001866

Source DB:  PubMed          Journal:  BMJ Support Palliat Care        ISSN: 2045-435X            Impact factor:   3.568


  5 in total

Review 1.  Malignant Bowel Obstruction Management Over Time: Are We Doing Anything New? A Current Narrative Review.

Authors:  Farhana Shariff; Jessica Bogach; Keegan Guidolin; Ashlie Nadler
Journal:  Ann Surg Oncol       Date:  2021-10-18       Impact factor: 5.344

2.  Endoscopically placed venting gastrostomy can be a safe and effective palliative intervention in benign and malignant gastrointestinal obstruction.

Authors:  Ross J Porter; Alastair W McKinlay; Emma L Metcalfe
Journal:  Frontline Gastroenterol       Date:  2021-09-20

3.  In Search of the Optimal Outcome Measure for Patients with Advanced Cancer and Gastrointestinal Obstruction: A Qualitative Research Study.

Authors:  Loretta A Williams; Eduardo Bruera; Brian Badgwell
Journal:  Ann Surg Oncol       Date:  2020-03-09       Impact factor: 5.344

4.  Symptom burden and lived experiences of patients, caregivers and healthcare professionals on the management of malignant bowel obstruction: A qualitative systematic review.

Authors:  Elin Baddeley; Mala Mann; Alison Bravington; Miriam J Johnson; David Currow; Fliss E M Murtagh; Elaine G Boland; George Obita; Alfred Oliver; Kathy Seddon; Annmarie Nelson; Jason W Boland; Simon I R Noble
Journal:  Palliat Med       Date:  2022-03-08       Impact factor: 5.713

5.  MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.

Authors:  Ainhoa Madariaga; Jenny Lau; Arunangshu Ghoshal; Tomasz Dzierżanowski; Philip Larkin; Jacek Sobocki; Andrew Dickman; Kate Furness; Rouhi Fazelzad; Gregory B Crawford; Stephanie Lheureux
Journal:  Support Care Cancer       Date:  2022-03-10       Impact factor: 3.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.